INTRODUCTION
============

Although endemic malaria is not seen in the United States of America (USA), majority of infections are caused by travel to or from endemic places of malaria transmission. The World Tourism Organization estimates that there were 1 billion international travelers in 2010, with notable increase in travel to Africa and South Asia \[[@b1-kjp-54-3-261]\]. With the increase of travel and increase of immigrants, number of cases of malaria in USA has also been increasing \[[@b2-kjp-54-3-261]\]. The prevention messages and health communication strategies have become even more important for protecting the traveling community from communicable diseases like malaria. Centers for Disease Control and Prevention (CDC), USA in 2010 reported a total of 1,688 cases of imported malaria in USA which was a 14% increase when compared to 2009 \[[@b3-kjp-54-3-261]\]. Imported malaria is defined as malaria acquired outside of USA and its territories. The aim of our study is to determine epidemiological characteristics and disease course of imported malaria in our hospital over the last 15 years.

MATERIALS AND METHODS
=====================

A retrospective chart review of 15 years (1998-2012) was performed to determine the number of malaria cases in adults, i.e., individuals greater than 18 years of age at Howard University Hospital, a semi-urban hospital of District of Columbia, USA. The cases were identified based on discharge diagnosis of malaria and those that had definite diagnosis of malaria were chosen. The cases were defined as definite if the results of a blood smear with Wright-Giemsa stain were positive for malarial parasites. The degree of parasitemia quantitatively accessed at the time of diagnosis could only be retrieved for patients diagnosed and treated after 2008.

The records of 37 patients with malaria during the study period were reviewed for demographic data, including the age, sex, place of origin, travel history, initial diagnosis, and prophylaxis, along with prior history of malaria and month and year of admission. The various presenting symptoms and complications were recorded. Laboratory data were also reviewed and included complete blood cell counts, blood chemistries, and blood smears. Incubation period was defined as interval between dates of arrival at USA to the time of onset of symptoms. The initial diagnosis (usually recorded as the admitting diagnosis on the discharge summary) was recorded. The duration of illness from time of onset of symptoms to presentation in the hospital and their length of stay in hospital were recorded. The antimalarial treatment and response of the patient to the therapy was noted as well. The data were analyzed, and means and percentages were calculated. The results are presented as the histogram, pie chart, and line diagram. The results were compared to CDC data on malaria.

Travelers were defined as persons from USA travelled to endemic area of malaria and returned back. Immigrants with recent travel were defined as persons from endemic areas of malaria living in USA and travelled to endemic areas. Immigrants were defined as persons who moved to USA from malaria endemic areas.

RESULTS
=======

All 37 cases in our study were of imported malaria. The diagnosis was confirmed by Giemsa stained thick and thin films of patient's peripheral blood. Their mean age was 38 years ranging from 20 to 66 years ([Fig. 1](#f1-kjp-54-3-261){ref-type="fig"}), of which there were 24 males (65%). African American accounted for the majority with 26 (70%), followed by Asian 1 (3%), and race was unknown in 10 patients (27%). The majority of cases, 8 (22%), were seen in September ([Fig. 2](#f2-kjp-54-3-261){ref-type="fig"}).

Eighteen (49%) were travelers, and most common place of travel was Nigeria 20 (54%) ([Fig. 3](#f3-kjp-54-3-261){ref-type="fig"}). Only 4 (11%) patients received chemoprophylaxis and a known past history of malaria was documented in 10 (27%) of the cases. The majority (31/37) of the patients presented with fever and chills (84%), followed by headache in 19 cases (51%) and generalized body aches in 12 cases (32%). The majority (31/37; 84%) of cases were diagnosed with *P. falciparum*, and 3 (8%) with *P. vivax*. The degree of parasitemia was available in 18 patients diagnosed and treated after 2008, which ranged from 0.001% to 0.3%. All the 3 patients with *P. vivax* were treated with chloroquine with proguanil. Among the 31 patients with *P. falciparum*, 14 (45%) were treated with quinine along with clindamycin/doxycycline, 13 (42%) received treatment with mefloquine, and 4 (13%) were given atovaquone-proguanil. The most common laboratory abnormality noted was thrombocytopenia in 27 (73%) of patients, followed by abnormal liver function tests in 30%. The majority (84%) of patients had uncomplicated malaria, and complicated malaria was seen only in 16% of patients based on WHO criteria as shown in [Table 1](#t1-kjp-54-3-261){ref-type="table"}. The mean length of hospital stay was 3.5 days with a mortality rate of 2.7%.

DISCUSSION
==========

Malaria is a vector-borne, febrile illness caused by *Plasmodium* species which is transmitted by the bite of female anopheline mosquito. *P. vivax*, *P. falciparum*, *P. ovale*, *P. malariae*, and *P. knowlesi* are the 5 species of plasmodia, which have been identified to cause human malaria. Malaria due to *P. falciparum* is the most deadly, and it predominates in Africa. *P. vivax* is less dangerous but is more widespread, and the other 3 species are found much less frequently \[[@b4-kjp-54-3-261]\]. It is important to study malaria cases in USA as it is one of the preventable and treatable diseases, if current recommended interventions are properly implemented; prompt initiation of treatment for malaria is important to avoid mortality associated with it \[[@b5-kjp-54-3-261],[@b6-kjp-54-3-261]\].

Malaria can present similarly as any other febrile illness, and the most commonly presented symptom would be fever with chills which was seen in 84% of our patients. Other symptoms of malaria include nausea, vomiting, malaise, weakness, headache, diarrhea, abdominal pain, and coma \[[@b7-kjp-54-3-261]\]. The most common complication in our patients was thrombocytopenia compared to acute respiratory distress syndrome (ARDS), renal insufficiency, and cerebral malaria in a study done on imported malaria in US travelers \[[@b8-kjp-54-3-261]\].

The incubation period of malaria varies between 7 to 420 days based on the species. The incubation period for *P. falciparum* can vary from 9 to 14 days but also be as short as 7 days; the period for *P. vivax* is 12 to 17 days, and that for *P. malariae* is as long as 18 to 40 days \[[@b9-kjp-54-3-261],[@b10-kjp-54-3-261]\]. Hypnozoites which are the dormant form can remain in the hepatocytes with *P. vivax* and *P. ovale* infections and can cause recurrent infection months or years after the initial infection. Our patients had a mean incubation period of 8 days as 94% of them had *P. falciparum*. We also found that 70% of imported malaria cases were travelers, and chemoprophylaxis was taken by only 4 (11%) patients. One patient took mefloquine, 1 pyrimethamine, the other took doxycycline, and unknown in the last one. Similarly from the CDC data of imported malaria in USA, only 5% of the patients reported taking chemoprophylaxis. This fact confirms the importance of using more sufficient preventive measures for travelers specially travelers visiting friends and relatives in endemic areas \[[@b3-kjp-54-3-261]\]. Another interesting aspect of our study was that among the 28% of cases who were immigrants, a previous history of malaria was given in 10 patients (27%), and all of them (100%) had *P. falciparum*. So, it is important to make patients admitted for *P. falciparum* malaria aware of the importance of chemoprophylaxis on revisiting those endemic areas for malaria as 1 time infection does not provide any immunity towards recurrent malaria.

In our study, 94% and 8% of the cases were diagnosed with *P. falciparum* and *P. vivax*, respectively. In contrast to these findings, the distribution of imported malaria species in Aukland, New Zealand was reported to be 52.9% *P. falciparum* and 47.1% *P. vivax*, where a major part of the investigated population was Indian migrants \[[@b11-kjp-54-3-261]\], and in another study by Stark et al. \[[@b12-kjp-54-3-261]\] reported 70% of *P. vivax* as the main species of imported malaria cases from Pakistan to Germany \[[@b12-kjp-54-3-261]\]. These findings are consistent with the fact that *P. falciparum* predominates in African countries, and *P. vivax* predominates in Asian countries. Similar results were seen with imported malaria cases in USA that 72% from Africa were *P. falciparum* and 74% from Asia were *P. vivax* \[[@b13-kjp-54-3-261]\].

Traditionally, preparation of thick and thin peripheral blood smear with Giemsa stain and demonstration of malaria parasites in RBC is the gold standard of diagnosing malaria. As expertise is needed in diagnosing this infection from the smear especially in countries where the disease is not endemic, the diagnostic trial could result in false negative, and lack of resources can contribute to misdiagnosis in endemic countries \[[@b14-kjp-54-3-261]\]. Now a newer method, like rapid diagnostic test (RDT), is available to diagnose malaria by detecting circulating malarial antigen; however, it cannot aid in quantification or identification of *Plasmodium* species. So, still a blood smear is needed to confirm the diagnosis \[[@b15-kjp-54-3-261],[@b16-kjp-54-3-261]\]. PCR is also available to diagnose malaria which is especially used in patients with a high suspicion for malaria with negative blood smears.

We also noted that the majority of cases were from West Africa with the peak month of incidence during September ([Fig. 2](#f2-kjp-54-3-261){ref-type="fig"}), although CDC surveillance showed a peak incidence in July and January for patients who traveled to Africa due to the popular traveling time during holiday season in summer and early winter. However, this difference could be partially explained by travelers (including immigrants with recent travel) contributing to 70% of our cases, who usually return back at the end of summer vacation with reopening of schools. As per CDC data \[[@b3-kjp-54-3-261]\], it was found that the peak incidence of *P. falciparum* was seen in late August to early September as in our study where 94% of patients had *P. falciparum*. Similar to these findings, the end of summer was the peak time for malaria case reports in Germany among individuals returning or migrating from Pakistan \[[@b12-kjp-54-3-261]\].

Although this is a study involving a small number of patients, similar studies from a single institute were reported by Froude et al. \[[@b17-kjp-54-3-261]\] in which 51 imported malaria cases during 1986-1991 from their institute at Bronx, New York, USA were included, and Moore et al. \[[@b18-kjp-54-3-261]\] reported 59 imported malaria cases from their institute at Houston, Texas, USA during 1990-1993. In our study, with prompt diagnosis and initiation of treatment, a good prognosis was seen with a mean length of hospital stay of 3.5 days. Only 1 person (2.7%) died of complicated malaria in whom diagnosis and treatment was delayed as travel history was not revealed by the patient at the time of admission. Malaria is not a common infection in USA, so travel history is a key for early diagnosis, and most importantly any patient who has been in an endemic area in the year preceding the onset of malarial symptoms should be evaluated for the disease \[[@b2-kjp-54-3-261],[@b7-kjp-54-3-261]\].

Due to an increase in international travels, imported malaria should be considered as one of the differentials in patients presenting with febrile illness from the endemic areas of malaria. As malaria is a treatable and preventable disease, there is increased need for creating awareness amongst travelers regarding chemoprophylaxis for effective prevention of this disease.
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###### 

List of complications noted among our patients

  Complication                                                   Percentage
  -------------------------------------------------------------- ------------
  Respiratory distress and acute respiratory distress syndrome   10.8
  Renal Failure                                                  5.4
  Circulatory collapse                                           5.4
  Coagulopathy and disseminated intravascular coagulopathy       5.4
  Intravascular hemolysis/hemolytic anemia                       2.6
  Metabolic acidosis                                             2.6
